Replies to post #20157 on Mymetics Corp (MYMX)

[Work Harder]

Montanide ISA-51 Adjuvant

https://scholar.google.com/scholar?q=Montanide+ISA-51+Adjuvant&hl=en&as_sdt=0&as_vis=1&oi=scholart

Breast Cancer Vaccine Moves into Phase 2 Clinical Trial

https://www.precisionvaccinations.com/her-vaxx-showed-success-stimulating-production-her-2-antibodies-early-stage-cancer-patients

immunoadjuvant montanide ISA 51, with potential immunostimulatory and antineoplastic activities.

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwj-xavbrOHrAhUzoXIEHSSoC2sQFjAIegQICRAB&url=https%3A%2F%2Fdigitalcommons.unl.edu%2Fcgi%2Fviewcontent.cgi%3Farticle%3D1340%26context%3Dusarmyresearch&usg=AOvVaw3rVkt2-Rd353MrAvUjBxUV

Particle-based platforms for malaria vaccines

Yimin Wua,*, David L. Naruma, Sylvain Fleuryb, Gary Jenningsc,1, Anjali Yadavad

Pfs25 formulated
with Montanide® ISA51, a water-in-oil formulation

They have been
widely used in vaccine development, and the O/W emulsion MF59
and AS03, and W/O emulsion Montanide® ISA51 are components
of several licensed vaccines [51].

Despite superb
immune-enhancement offered by Montanide® ISA51 and a similar
W/O emulsion Montanide® ISA720, the adjuvants ceased to
be the choice for clinical development due to high rate of local
reactogenicity and unexpected systemic reactions in Phase 1 trials

Be safe